New Hepatitis C Treatment

Published Online: Friday, February 24, 2012
Follow Pharmacy_Times:
The standard treatment for hepatitis C, interferon and ribavirin, cures just 45% of those who receive it. There are now several dozen new drugs for the disease under development, and 2 were approved by the FDA in 2011: telaprevir and boceprevir. The new drugs, which directly attack the virus that causes hepatitis C with minimal impact on the human host, have raised hopes of shorter treatment times and higher cure rates. Researchers are also looking at ways of tailoring treatment to individual patients based on genetic testing.
To learn more, check out this video:

Related Articles
AbbVie and Gilead are fighting over hepatitis C drug market share.
Eric Tichy, PharmD, BCPS, FCCP, senior clinical pharmacy specialist at Yale New-Haven Hospital, explains how hepatitis C therapies are changing patient treatment.
Valeant Pharmaceuticals of Bridgewater, NJ, has issued a voluntary recall of one lot of Virazole®(ribavirin powder for solution), 100 mL, 6g vial, 4-pack to the user level.
Valeant Pharmaceuticals is voluntarily recalling a lot of its ribavirin powder for solution (Virazole) to the user level due to microbial contamination.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times